WHAT TO EXPECT FROM THE NEW MERCK ANTIVIRAL PILL
On Friday, October 1, the multinational pharmaceutical company Merck and Ridgeback Biotherapeutics announced some welcome news about a promising at-home treatment for COVID-19. Merck shared the results of its 3rd phase trials for its recently acquired drug, Molnupiravir (a.k.a. MK-4482, EIDD-2801). According to the press release, “Molnupiravir reduced the risk of hospitalization or death by […]
